Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Lordick

Showing results (91-100 of 114) with videos related to

Pageof 12
Sort By:
ESMO Open|August 15, 2024
Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trialsF Lordick, E Van Cutsem, K Shitara, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|February 5, 2013
A reliable risk score for stage IV esophagogastric cancerS Blank, F Lordick, M Dobritz, et al.
ESMO Open|March 4, 2023
Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicinesG Zarkavelis, A L Amylidi, C Verbaanderd, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 21, 2021
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinomaU Sahin, Ö Türeci, G Manikhas, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
European screening platform for EORTC clinical trials in advanced colorectal cancer 'SPECTAcolor'G Folprecht, M Morfouace, M Collienne, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2013
Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancerM Peeters, T J Price, A Cervantes, et al.
ESMO Open|June 4, 2023
S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma-final results of the randomized AIO MATEO phase II trialG Stocker, S Lorenzen, T Ettrich, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
Local and central testing for HER2, PD-L1, MSI/MMR, EBV, and CLDN18.2 in advanced gastric cancer: results from the SAPHIR registryK Potthoff, H Bläker, T Dechow, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 27, 2019
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO studyO Türeci, U Sahin, H Schulze-Bergkamen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)M Moehler, A Maderer, P C Thuss-Patience, et al.
Pageof 12

Showing results (91-100 of 114) with videos related to

Sort By:
Pageof 12
ESMO Open|August 15, 2024
Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trialsF Lordick, E Van Cutsem, K Shitara, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|February 5, 2013
A reliable risk score for stage IV esophagogastric cancerS Blank, F Lordick, M Dobritz, et al.
ESMO Open|March 4, 2023
Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicinesG Zarkavelis, A L Amylidi, C Verbaanderd, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 21, 2021
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinomaU Sahin, Ö Türeci, G Manikhas, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
European screening platform for EORTC clinical trials in advanced colorectal cancer 'SPECTAcolor'G Folprecht, M Morfouace, M Collienne, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2013
Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancerM Peeters, T J Price, A Cervantes, et al.
ESMO Open|June 4, 2023
S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma-final results of the randomized AIO MATEO phase II trialG Stocker, S Lorenzen, T Ettrich, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
Local and central testing for HER2, PD-L1, MSI/MMR, EBV, and CLDN18.2 in advanced gastric cancer: results from the SAPHIR registryK Potthoff, H Bläker, T Dechow, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 27, 2019
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO studyO Türeci, U Sahin, H Schulze-Bergkamen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)M Moehler, A Maderer, P C Thuss-Patience, et al.
Pageof 12